Infliximab-associated reversible cholestatic liver disease.
Infliximab, a novel therapy for Crohn disease, has been shown to be both safe and effective. We describe a 44-year-old woman with Crohn disease who developed jaundice after an infusion of infliximab. Multiple investigations were undertaken, cholestatic liver disease was diagnosed, and her condition improved with supportive therapy. Although likely a rare adverse event, cholestatic liver injury should be considered in patients presenting with jaundice who have received infliximab therapy.
Menghini
V V
VV
Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Arora
A S
AS
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002779:Cholestasis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008099:Liver / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab